US 12,570,674 B2 · Boron carrying agent for integrated tumor diagnosis and treatment, and preparation method therefor and use thereof

Abstract

The present invention relates to a boron carrying agent for integrated tumor diagnosis and treatment, and a preparation method therefor and use thereof. Provided is a compound represented by formula I: wherein an R group is hydrogen or alkyl. A boron atom connected to the benzene ring may be 10B or natural boron, and at least one fluorine atom in —BF 3- is radiolabeled. The present invention generally relates to the fields of radiopharmaceuticals and nuclear medicine. The compound in the present invention can be used for a drug for integrated diagnosis and treatment in tumor diagnosis and BNCT treatment, and by means of the same chemical structure, a reliable distribution result of a drug in vivo is provided.

Claims14

Dependent claims

A compound of Formula I:

wherein, R group is hydrogen, alkyl, or methyl.

Dependencies are inferred from the claim text.

Facts

Application

17/908,630Filed 1 Mar 2021

Priority

CN 202010137553.73 Mar 2020

Published

US 2023/0312611 A15 Oct 2023

Granted

10 Mar 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification12 codes

A61P 35/02
Antineoplastic agents: specific for leukemia
C07F 5/025
Boron compounds: boronic and borinic acid compounds
A61K 41/0095
Neutron capture therapy, e.g. using uranium or non-boron material: boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
A61K 51/04
Characterised by the carrier , i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus: organic compounds

Boron carrying agent for integrated tumor diagnosis and treatment, and preparation method therefor and use thereof

Life of this patent

Boron carrying agent for integrated tumor diagnosis and treatment, and preparation method therefor and use thereof

Life of this patent

Abstract

Claims14